Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Data on Fabrazyme® (agalsidase Beta) for People with Fabry Disease
Details : Fabrazyme (agalsidase beta) works by replacing a naturally occurring enzyme (alpha-galactosidase A) to help clear GL-3 build-up in cells, including those lining the blood vessels of the kidneys, heart and skin. It is the only FDA-approved therapy for Fab...
Product Name : Fabrazyme
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Biosidus
Deal Size : Undisclosed
Deal Type : Agreement
mAbxience and Biosidus Sign CDMO agreement for agalsidase beta in Fabry disease
Details : mAbxience will manufacture the biosimilar of Fabrazyme (agalsidase beta), developed by Biosidus, for Fabry disease treatment under the agreement.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 02, 2024
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Biosidus
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : ISU ABXIS
Deal Size : Inapplicable
Deal Type : Inapplicable
Fabagal® for Fabry Disease Management is Now Available in Russia
Details : Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Product Name : Fabagal
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : ISU ABXIS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Petrovax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Product Name : Fabagal
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Petrovax
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Sumitomo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement includes the marketing alliance for JR-051 (agalsidase beta BS), a biosimilar of Fabrazyme, a therapeutic enzyme, being sold by JCR for the treatment of Fabry disease.
Product Name : JR-051
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 03, 2022
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Sumitomo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
